To Assess the Role of to Cilizumab with or without Remdesivir in Covid-19 Diabetic Patients

ABSTRACT

Background: The clinical presentation of Covid-19 positive person can range from asymptomatic to severe pneumonia with acute respiratory diseases. The major impact of Covid-19 is identified on respiratory system of the human and leading to death. There are different types of treatment options available for managing the health of the people but first was remdesivir that approved by the FDA. The dexamethasone has been associated with decreased mortality in recovery of the medicine trail. Apart from this, the major benefits of interleukin 6 antagonists are still subject of debate as tocilizumab FDA approved the interleukin 6 for treatment considering the side effects too. Aim: The study aims to assess the role of tocilizumab with or without remdesivir in COVID-19 diabetic patients Method: The current study is retrospective, single centered, observational cohort and based on the patients who were diagnosed with Covid-19 considering the PCR test and hospitalized at ESI Chitrakoot Nagar, Udaipur under RNT Medical College, Udaipur from October-20 to December-21. The study has involved the patients who were 18 years and older and had the clinical association with diabetes mellitus. Moreover, the respiratory findings also defined as infiltrates, SPO2 < 93% on room air and requirements of respiratory assistance. For the current study, the data was collected related to demographics, co-morbidities, symptom, oxygen support category, laboratory values and outcome of the therapies. The level of oxygen support was analyzed considering the ACTT-1. Results: There were total of 127 patients considered for analyzing the role of tocilizumab with or without remdesivir in COVID-19 diabetic patients. The group 1 is involving the 54 patients and group 2 has 73 covid-19 patients. According to the outcome of the analysis, the mean age of both groups were 62 and 64 years for group 1 and 2. There was significant difference identified for respiratory support received by the patients and obesity, COPD and CVD. However, there was no significant difference found for diabetes patients as the P value was more than 0.05. As per the outcome of the study focusing on the Chi Square, most of the variables have shown significant difference but Remdesivir, and low vitamin D levels have shown the no significant difference Conclusion: From the analysis, it has been concluded that the combinations of tocilizumab and remdesivir did not have any significant difference in mortality but the patients who recovered from the covid-19 has influenced with diabetic issues. The improvement in practice and advancement in laboratory trail has helped to improve the effectiveness of these treatment options.